Proactive Investors - Analysts at Citi have revised their net present value (NPV)-based price target for Hikma Pharmaceuticals PLC (LON:HIK) to £19.20 with a...
Vaccines manufactured by three groups have so far been approved in the UK. They include:AstraZeneca (LON:AZN) (NASDAQ:AZN)/ Oxford University; BioNTech (NASDAQ:BNTX) / Pfizer...
Recent positive news about a COVID-19 vaccine has put the limelight on health-care and pharmaceutical companies, especially BioNTtech (NASDAQ:BNTX), Moderna (NASDAQ:MRNA) and...
Equities are showing decent gains as we approach the end of the trading session. Europe There was some indecision in the first few hours of trading as stocks got off to a strong...
Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing, marketing and selling of a broad range of generic, branded and in-licensed pharmaceuticals products in solid, semi-solid, liquid and injectable final dosage forms. The Company operates through three segments, such as Injectables, Generics and Branded. The Injectables business develops and manufactures generic injectable products, which are primarily used in hospitals. The Generics business develops and manufactures oral and other non-injectable generic products. The Branded business develops and manufactures branded generics and markets and sells in-licensed patented products in Middle East/North Africa (MENA). The Company’s products are sold in the retail and hospital markets. It also markets its products in Canada, which includes approximately 25 sterile injectable products, three in-licenced ophthalmic products and a pipeline of seven additional products.